IIIA期非小细胞肺癌同步放化疗后解剖性切除的短期结果
基于NRG Oncology两项前瞻试验(RTOG 0229和0839),评估可切除N2+ IIIA期NSCLC患者接受铂类化疗联合全剂量胸部放疗后解剖性切除的早期安全性。93例(74%)接受解剖性切除,91%切缘阴性,3/4级手术不良事件28%,30天死亡率4%,90天死亡率5%;扩大切除者30天和90天死亡率显著升高。
要点
- 全剂量同步放化疗后肺叶切除安全可行,切缘阴性率91%。
- 扩大切除与30天和90天死亡率升高相关。
- 3/4级手术不良事件发生率28%,30天死亡率4%。
核心结论
- 全剂量同步放化疗后肺叶切除在多中心前瞻试验中安全可行,但扩大切除死亡率增加。
研究设计与样本
- NRG Oncology两项前瞻试验(RTOG 0229和0839),入组可切除N2+ IIIA期NSCLC患者,诱导为每周卡铂(AUC 2.0)和紫杉醇(50 mg/m2)联合同步胸部放疗60 Gy(0839)/61.2 Gy(0229)分30次。
主要发现
- 85例(91%)达到镜下切缘阴性。
- 26例(28%)发生3或4级手术不良事件,30天死亡率4%(4例),90天死亡率5%(5例)。
- 扩大切除者3/4级不良事件率相似(OR 0.95,95%CI 0.42-3.8),但30天死亡率(1.3% vs 18.8%,OR 17.54,95%CI 1.75-181.8)和90天死亡率(2.6% vs 18.8%,OR 8.65,95%CI 1.3-56.9)更高。
临床怎么用
- 对于可切除N2+ IIIA期NSCLC,全剂量同步放化疗后可行肺叶切除,但需谨慎评估扩大切除的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Concern exists regarding surgery after thoracic radiation. We aimed to assess early results of anatomic resection following induction therapy with platinum-based chemotherapy and full-dose thoracic radiation for resectable N2+ stage IIIA non-small cell lung cancer. METHODS: Two prospective trials were recently conducted by NRG Oncology in patients with resectable N2+ stage IIIA non-small cell lung cancer with the primary end point of mediastinal node sterilization following concurrent full-dose chemoradiotherapy (Radiation Therapy Oncology Group trials 0229 and 0839). All surgeons demonstrated postinduction resection expertise. Induction consisted of weekly carboplatin (area under the curve, 2.0) and paclitaxel (50 mg/m2) and concurrent thoracic radiation 60 Gy (0839)/61.2 Gy (0229) in 30 fractions. Patients in study 0839 were randomized 2:1 to weekly panitumumab + chemoradiotherapy or chemoradiotherapy alone during induction. Primary results were similar in all treatment arms and reported previously. Short-term surgical outcomes are reported here. RESULTS: One hundred twenty-six patients enrolled; 93 (74%) had anatomic resection, 77 underwent lobectomy, and 16 underwent extended resection. Microscopically margin-negative resections occurred in 85 (91%). Fourteen (15%) resections were attempted minimally invasively, including 2 converted without event. Grade 3 or 4 surgical adverse events were reported in 26 (28%), 30-day mortality in 4 (4%) and 90-day mortality in 5 (5%). Patients undergoing extended resection experienced similar rates of grade 3 or 4 adverse events (odds ratio, 0.95; 95% confidence interval, 0.42-3.8) but higher 30-day (1.3% vs 18.8%) (odds ratio, 17.54; 95% confidence interval, 1.75-181.8) and 90-day mortality (2.6% vs 18.8%) (odds ratio, 8.65; 95% confidence interval, 1.3-56.9). CONCLUSIONS: Lobectomy was performed safely following full-dose concurrent chemoradiotherapy in these multi-institutional prospective trials; however, increased mortality was noted with extended resections.
引用
- Donington JS, Paulus R, Edelman MJ, et al. Resection following concurrent chemotherapy and high-dose radiation for stage IIIA non-small cell lung cancer. J Thorac Cardiovasc Surg. 2020. PMID: 32798022. doi:10.1016/j.jtcvs.2020.03.171
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。